AWH - Aspira Women's Health Inc.
0.082
-0.012 -14.268%
Share volume: 4,742,494
Last Updated: 04-16-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
$0.09
-0.01
-0.12%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-15-2024 | 08-13-2024 | 11-19-2024 | 03-27-2025 | 05-19-2025 | 08-12-2025 | 11-14-2025 | |
| Total revenue | 2.153 M | 2.423 M | 2.257 M | 2.349 M | 2.279 M | 2.404 M | 2.305 M | |
| Cost of revenue | 939.000 K | 1.002 M | 902.000 K | 860.000 K | 719.000 K | 870.000 K | 922.000 K | |
| Gross profit | 1.214 M | 1.421 M | 1.355 M | 1.489 M | 1.560 M | 1.534 M | 1.383 M | |
| 17.05% | -4.64% | 9.89% | 4.77% | -1.67% | -9.84% | |||
| Operating expenses | 4.035 M | 3.677 M | 2.956 M | 2.943 M | 3.714 M | 2.665 M | 2.279 M | |
| Selling general and admin | 3.129 M | 2.725 M | 2.048 M | 2.443 M | 2.741 M | 1.961 M | 1.540 M | |
| Research and development | 906.000 K | 952.000 K | 908.000 K | 500.000 K | 973.000 K | 704.000 K | 739.000 K | |
| Total expenses | 5.924 M | 5.814 M | 5.099 M | 4.920 M | 4.800 M | 3.344 M | 2.962 M | |
| -1.86% | -12.30% | -3.51% | -2.44% | -30.33% | -11.42% | |||
| Operating income | -4.710 M | -4.393 M | -3.744 M | -3.431 M | -3.240 M | -1.810 M | -1.579 M | |
| Ebit | -4.624 M | -3.520 M | -3.542 M | -1.375 M | -1.839 M | -2.434 M | -5.888 M | |
| Pretax income | -4.629 M | -3.530 M | -3.547 M | -1.388 M | -1.853 M | -2.447 M | -5.901 M | |
| -23.74% | 0.48% | -60.87% | 33.50% | 32.06% | 141.15% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.629 M | -3.530 M | -3.547 M | -1.388 M | -1.853 M | -2.666 M | -4.892 M | |
| 23.74% | -0.48% | 60.87% | -33.50% | -43.87% | -83.50% |